A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis

BACKGROUND: Teriflunomide is a once-daily oral immunomodulator for the treatment of relapsing−remitting MS. OBJECTIVE: To evaluate the safety and tolerability of teriflunomide as add-on therapy to a stable dose of glatiramer acetate (GA) in patients with relapsing forms of MS (RMS). METHODS: Phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Freedman, MS, Wolinsky, JS, Truffinet, P, Comi, G, Kappos, L, Miller, AE, Olsson, TP, Benamor, M, Chambers, S, O’Connor, PW
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433345/
https://www.ncbi.nlm.nih.gov/pubmed/28607708
http://dx.doi.org/10.1177/2055217315618687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433345/
https://www.ncbi.nlm.nih.gov/pubmed/28607708
http://dx.doi.org/10.1177/2055217315618687

Ejemplares similares